Prime Medicine, Inc. (PRME) Financial Ratios
7 years of historical data (2019–2025) · Healthcare · Biotechnology
EV/EBITDA
N/A
—
5yr avg: N/A
P/FCF
N/A
—
5yr avg: N/A
P/B Ratio
↓
3.83
↓-16% vs avg
5yr avg: 4.57
30Y Low2.3·High6.1
ROE
↓
-146.8%
↑-37% vs avg
5yr avg: -107.4%
30Y Low-182%·High-20%
Debt/EBITDA
N/A
—
5yr avg: N/A
Percentile shows where the current value sits in 30-year historical distribution. Sparklines show 5-year trend.
PRME Valuation Multiples
Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow
Prime Medicine, Inc. currently has a negative P/E ratio, indicating the company is operating at a loss on a trailing-twelve-month basis.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|---|---|
| Market Cap | $562M | $516M | $346M | $806M | $1.8B | — | — | — |
| Enterprise Value | $616M | $570M | $205M | $778M | $1.6B | — | — | — |
| P/E Ratio → | -2.31 | — | — | — | — | — | — | — |
| P/S Ratio | 121.42 | 111.44 | 116.10 | — | — | — | — | — |
| P/B Ratio | 3.83 | 4.27 | 2.26 | 6.06 | 5.71 | — | — | — |
| P/FCF | — | — | — | — | — | — | — | — |
| P/OCF | — | — | — | — | — | — | — | — |
P/E links to full P/E history page with 30-year chart
PRME EV Ratios
Enterprise-value multiples — capital-structure-neutral measures of total business value
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|---|---|
| EV / Revenue | — | 122.97 | 68.60 | — | — | — | — | — |
| EV / EBITDA | — | — | — | — | — | — | — | — |
| EV / EBIT | — | — | — | — | — | — | — | — |
| EV / FCF | — | — | — | — | — | — | — | — |
PRME Profitability
Margins and return-on-capital ratios measuring operating efficiency
Prime Medicine, Inc. earns an operating margin of -4498.1%. Operating margins have expanded from -6787.4% to -4498.1% over the past 3 years, signaling improving operational efficiency. A negative ROE of -146.8% indicates the company is currently destroying shareholder equity.
Margins
Full margin charts and quarterly trend are on the Earnings History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|---|---|
| Gross Margin | -58.1% | -58.1% | 100.0% | — | — | — | 42.8% | — |
| Operating Margin | -4498.1% | -4498.1% | -6787.4% | — | — | — | -17.9% | — |
| Net Profit Margin | -4342.4% | -4342.4% | -6566.6% | — | — | — | -65.5% | — |
Return on Capital
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|---|---|
| ROE | -146.8% | -146.8% | -136.9% | -88.2% | -43.8% | -121.1% | -19.6% | -182.1% |
| ROA | -62.8% | -62.8% | -79.7% | -71.5% | -36.8% | -92.7% | -10.7% | -29.1% |
| ROIC | -168.3% | -168.3% | -260.5% | -117.0% | -78.8% | -207.6% | — | — |
| ROCE | -73.8% | -73.8% | -102.0% | -87.0% | -40.4% | -60.5% | -5.1% | -156.4% |
PRME Leverage & Debt
Solvency and debt-coverage ratios — lower is generally safer
Net debt stands at $53M ($116M total debt minus $63M cash).
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 0.96 | 0.96 | 0.27 | 0.10 | 0.09 | 0.04 | — | — |
| Debt / EBITDA | — | — | — | — | — | — | — | — |
| Net Debt / Equity | — | 0.44 | -0.93 | -0.21 | -0.50 | -0.73 | -1.10 | -6.23 |
| Net Debt / EBITDA | — | — | — | — | — | — | — | -1.99 |
| Debt / FCF | — | — | — | — | — | — | — | — |
| Interest Coverage | — | — | — | — | — | — | — | — |
PRME Liquidity & Efficiency
Short-term solvency ratios and asset-utilisation metrics
Prime Medicine, Inc.'s current ratio of 4.84x is well above the 1.0 safety threshold, indicating strong short-term liquidity with ample room to cover current liabilities. The current ratio has improved from 2.53x to 4.84x over the past 3 years.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|---|---|
| Current Ratio | 4.84 | 4.84 | 5.58 | 2.53 | 11.10 | 4.67 | 2.75 | 1.19 |
| Quick Ratio | 4.84 | 4.84 | 5.58 | 2.53 | 11.10 | 4.67 | 2.75 | 1.19 |
| Cash Ratio | 4.74 | 4.74 | 5.02 | 2.16 | 11.00 | 4.65 | 2.74 | 1.18 |
| Asset Turnover | — | 0.01 | 0.01 | — | — | — | 0.10 | — |
| Inventory Turnover | — | — | — | — | — | — | — | — |
| Days Sales Outstanding | — | — | — | — | — | — | — | — |
PRME Shareholder Yields
Earnings, FCF, buyback, and dividend yields — total returns to shareholders
Prime Medicine, Inc. does not currently pay a dividend and has no material buyback yield, reinvesting earnings back into the business.
Dividends
Full dividend history and growth charts are on the Dividend History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|---|---|
| Dividend Yield | — | — | — | — | — | — | — | — |
| Payout Ratio | — | — | — | — | — | — | — | — |
Total Shareholder Return Metrics
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|---|---|
| Earnings Yield | — | — | — | — | — | — | — | — |
| FCF Yield | — | — | — | — | — | — | — | — |
| Buyback Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | — | — | — |
| Total Shareholder Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | — | — | — |
| Shares Outstanding | — | $149M | $119M | $91M | $97M | $96M | $96M | $96M |
Peer Comparison
Compare PRME with 10 similar companies in its peer group
| Company | Market Cap | P/E | EV/EBITDA | P/FCF | Gross Margin | Op Margin | ROE | ROIC | Debt/EBITDA |
|---|---|---|---|---|---|---|---|---|---|
 PRMEYou | $562M | -2.3 | — | — | -58.1% | -4498.1% | -146.8% | -168.3% | — |
 BEAM | $3B | -38.9 | — | — | 84.0% | -274.6% | -8.1% | -31.1% | — |
 CRSP | $5B | -8.1 | — | — | -6537.0% | -16191.4% | -30.2% | -22.3% | — |
 EDIT | $297M | -1.7 | — | — | — | — | -198.1% | — | — |
 NTLA | $2B | -3.6 | — | — | 76.5% | -651.7% | -53.5% | -44.0% | — |
 KRRO | $121M | -1.0 | — | — | 33.0% | -1366.4% | -110.7% | -58.8% | — |
 RCKT | $398M | -1.8 | — | — | — | — | -60.3% | -63.2% | — |
 SGMO | $22M | -0.2 | — | — | 100.0% | -179.9% | -185.4% | -178.8% | — |
 ILMN | $21B | 25.5 | 19.6 | 22.6 | 66.7% | 19.9% | 33.4% | 16.8% | 2.3 |
 PACB | $498M | -0.9 | — | — | 31.7% | -348.5% | -213.5% | -45.8% | — |
 TWST | $4B | -45.0 | — | — | 50.7% | -36.2% | -16.4% | -26.9% | — |
| Healthcare Median | — | 22.3 | 14.4 | 18.5 | 63.9% | -5.2% | -33.7% | -11.2% | 3.3 |
Peer selection based on competitive and market overlap. Compare multiple stocks →
Download Financial Ratios Data
Includes 30+ ratios · 7 years · Updated daily
See PRME's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs PRME Undervalued?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationCompare PRME vs BEAM
Side-by-side business, growth, and profitability comparison vs Beam Therapeutics Inc..
Start ComparisonPRME — Frequently Asked Questions
Quick answers to the most common questions about buying PRME stock.
What is Prime Medicine, Inc.'s P/E ratio?
Prime Medicine, Inc.'s current P/E ratio is -2.3x. This places it at the 50th percentile of its historical range.
What is Prime Medicine, Inc.'s ROE?
Prime Medicine, Inc.'s return on equity (ROE) is -146.8%. The historical average is -105.5%.
Is PRME stock overvalued?
Based on historical data, Prime Medicine, Inc. is trading at a P/E of -2.3x. This is at the 50th percentile of its historical P/E range. Compare with industry peers and growth rates for a complete picture.
What are Prime Medicine, Inc.'s profit margins?
Prime Medicine, Inc. has -58.1% gross margin and -4498.1% operating margin.